A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma (NCT05548296)

🧪 Interventions in This Study

• ACR-368 (DRUG)
• Gemcitabine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (90 Sites)

Showing the first 25 of 90 sites.

• University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
• Alaska Women's Cancer Center — Anchorage, Alaska
• HonorHealth — Phoenix, Arizona
• Arizona Oncology Associate, PC- HOPE — Tucson, Arizona
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• City of Hope National Medical Center — Duarte, California
• UC San Diego Moores Cancer Center — La Jolla, California
• USC/Norris Comprehensive Cancer Center — Los Angeles, California
• Cedars Sinai Medical Center — Los Angeles, California
• Hoag Cancer Center — Newport Beach, California
• UC Irvine Health — Orange, California
• Stanford Cancer Center — Palo Alto, California
• University of California, Davis Comprehensive Cancer Center — Sacramento, California
• University of California Los Angeles (UCLA) — Santa Monica, California
• University of Colorado — Aurora, Colorado
• Yale Cancer Center — New Haven, Connecticut
• Florida Gynecologic Oncology/Regional Cancer Center — Fort Myers, Florida
• Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
• Emory University — Atlanta, Georgia
• Northeast Georgia Medical Center — Gainesville, Georgia
• Northwestern Medicine — Chicago, Illinois
• University of Illinois Cancer Center — Chicago, Illinois
• University of Chicago Medicine — Chicago, Illinois
• Carle Cancer Center — Urbana, Illinois
• Ascension St. Vicent Hospital, Inc. — Indianapolis, Indiana

📞 Contact the Study Coordinator

Phone: (617) 207-8976

Email: ACR-368-201ClinicalTrial@acrivon.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Endometrial Adenocarcinoma

• Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer — Phoenix, Arizona
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone — Birmingham, Alabama
• Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment — Basking Ridge, New Jersey
• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma — Birmingham, Alabama

Explore by condition: All Endometrial Adenocarcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.